Early symptom improvement with risankizumab treatment in patients with moderately to severely active Crohn's disease: analysis from a Phase 2 study

(1) Robarts Clinical Trials Inc.,London,Canada

(2) University of California,San Diego,United States

(3) AMC Amsterdam Inflammatory Bowel Disease Centre,Amsterdam,Netherlands

(4) Hospital Clínic Barcelona,Barcelona,Spain

(5) University of Cambridge Gastroenterology and Hepatology,Cambridge,United Kingdom

(6) University Hospitals Leuven,Leuven,Belgium

(7) University Hospital CHU of Liège,Liège,Belgium

(8) UCL Saint Luc,Brussels,Belgium

(9) Hannover Medical School,Hannover,Germany

(10) Asan Medical Center,Seoul,Korea (Republic of)

(11) AbbVie,North Chicago,United States

(12) AbbVie Inc.,North Chicago,United States

(13) University of Erlangen-Nuremberg,Erlangen,Germany

This item was part of the Epidemiology and treatment of IBD session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019


  • Format
    • Abstract
  • Year
    • 2019